Superior efficacy of co-targeting GFI1/KDM1A and BRD4 against AML and post-MPN secondary AML cells

Superior efficacy of co-targeting GFI1/KDM1A and BRD4 against AML and post-MPN secondary AML cells

Abstract There is an unmet need to overcome nongenetic therapy-resistance to improve outcomes in AML, especially post-myeloproliferative neoplasm (MPN) secondary (s) AML. Studies presented describe effects of genetic knockout, degradation or small molecule targeted-inhibition of GFI1/LSD1 on active...

Full description

Bibliographic Details
Main Authors: Warren Fiskus, Christopher P. Mill, Behnam Nabet, Dimuthu Perera, Christine Birdwell, Taghi Manshouri, Bernardo Lara, Tapan M. Kadia, Courtney DiNardo, Koichi Takahashi, Naval Daver, Prithviraj Bose, Lucia Masarova, Naveen Pemmaraju, Steven Kornblau, Gautam Borthakur, Guillermo Montalban-Bravo, Guillermo Garcia Manero, Sunil Sharma, Matthew Stubbs, Xiaoping Su, Michael R. Green, Cristian Coarfa, Srdan Verstovsek, Joseph D. Khoury, Christopher R. Vakoc, Kapil N. Bhalla
Format: Article
Language:English
Published: Nature Publishing Group 2021-05-01
Series:Blood Cancer Journal
Online Access:https://doi.org/10.1038/s41408-021-00487-3

Internet

https://doi.org/10.1038/s41408-021-00487-3

Similar Items